Drug Trial Radar · NCT00486343
Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
Last checked: Nov 20, 2026Latest source record: Apr 3, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 2007
Primary completion
May 2008
Study completion Jun 2008
Sponsor
- Lead sponsor
- Critical TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Asthma is a chronic inflammatory disorder of the airways with a variety of inflammatory processes contributing to the pathogenesis. The inflammation leads to a state of increased airway responsiveness and reversible airway obstruction that causes the recurrent symptoms of asthma. Despite the variety of treatments available for asthma, none are curative, and the disease continues to place a burden on society in terms of morbidity, reduced quality of life (QOL), and ever increasing healthcare costs. The prevalence of asthma continues to increase with current data suggesting that since 1980, adult asthma cases have increased by 75% and in children under 5 years of age the prevalence has increased by 160%.1 Additionally, studies have suggested that the disease severity has been underestimated and that more patients may be classified as having moderate to severe persistent disease.2 Inhaled corticosteroids (ICS) have been the cornerstone of anti-inflammatory treatment for decades and have been shown to improve lung function, decrease symptoms, and reduce asthma exacerbations.3 However, many patients are still inadequately controlled despite treatment according to current asthma management guidelines and have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.4 Combining long-acting β2-agonists (LABAs) with low dose ICS has been shown to improve asthma control over using higher doses of ICS alone. However, LABAs act mainly at the bottom of the inflammatory cascade and there are concerns that they may mask underlying inflammation.5 Recently, leukotriene receptor antagonists have been added to ICS as second-line therapy in the management of asthma. Zileuton has been extensively studied in inflammatory diseases such as asthma, in which leukotrienes mediate inflammation. The aim of this study is to assess the effect of zileuton controlled-release (CR; 1200 mg 2-times daily \[BID\]) on pulmonary function, asthma control, and symptomatic response in adult patients with asthma poorly controlled on moderate dose ICS.
Conditions
- Asthma
Interventions
Zileuton CRDrug
Zileuton CR tablets 2x600mg BID for 24 weeks
PlaceboDrug
Placebo tablets 2x600mg BID for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pulmonary function measuresTime frame: 3 and 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Critical Therapeutics
Lexington, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.